Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Souders Financial Advisors

Souders Financial Advisors lessened its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 18.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,740 shares of the biopharmaceutical company’s stock after selling 613 shares during the quarter. Souders Financial Advisors’ holdings in Alnylam Pharmaceuticals were worth $645,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of ALNY. Geode Capital Management LLC increased its stake in Alnylam Pharmaceuticals by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company’s stock worth $589,209,000 after buying an additional 66,928 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 5.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 513,962 shares of the biopharmaceutical company’s stock worth $120,940,000 after purchasing an additional 26,614 shares during the last quarter. Swiss National Bank boosted its holdings in shares of Alnylam Pharmaceuticals by 0.3% during the 3rd quarter. Swiss National Bank now owns 375,400 shares of the biopharmaceutical company’s stock worth $103,246,000 after purchasing an additional 1,000 shares during the last quarter. Eagle Asset Management Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 25.7% during the 3rd quarter. Eagle Asset Management Inc. now owns 309,589 shares of the biopharmaceutical company’s stock worth $85,889,000 after purchasing an additional 63,385 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 3.0% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company’s stock worth $67,464,000 after purchasing an additional 8,462 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ALNY. HC Wainwright upped their price objective on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a “buy” rating in a report on Monday, February 24th. Royal Bank of Canada reiterated an “outperform” rating and issued a $310.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. StockNews.com cut Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 9th. Chardan Capital reiterated a “buy” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. Finally, Scotiabank decreased their price objective on Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating on the stock in a report on Friday, February 14th. One research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $304.26.

Insider Activity at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 52,592 shares of the stock in a transaction on Monday, January 27th. The stock was sold at an average price of $285.00, for a total value of $14,988,720.00. Following the transaction, the chief marketing officer now owns 11,989 shares of the company’s stock, valued at $3,416,865. This represents a 81.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total value of $362,246.40. Following the completion of the transaction, the executive vice president now directly owns 12,881 shares in the company, valued at $3,240,344.36. This trade represents a 10.06 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 72,986 shares of company stock valued at $20,397,849 over the last quarter. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Stock Up 2.6 %

Alnylam Pharmaceuticals stock opened at $249.23 on Thursday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39. The stock’s fifty day simple moving average is $254.34 and its 200-day simple moving average is $261.90. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The firm has a market capitalization of $32.26 billion, a P/E ratio of -114.85 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.